ArticleFrontiers in neurology

Anti-CGRP monoclonal antibody therapy for migraine is not associated with early adverse bone effects: a prospective, observational, controlled, cohort study.

Giulia Mallucci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.